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In the 2009 European Guidelines on the diagnosis and treatment of pulmonary hypertension (PH), one section
covers aspects of pathophysiology, diagnosis and treatment of chronic thromboembolic pulmonary hyperten-
sion (CTEPH). The practical implementation of the guidelines for this disease is of crucial importance, because
CTEPH is a subset of PH which can potentially be cured by pulmonary endarterectomy (PEA). Nowadays,
CTEPH is commonly underdiagnosed and not properly managed. Any patient with unexplained PH should be
evaluated for the presence of CTEPH, and a ventilation/perfusion (V/Q) lung scan is recommended as screen-
ing method of choice. If the V/Q scan or CT angiography reveals signs of CTEPH, the patient should be referred
to a specialized center with expertise in the medical and surgical management of this disease. Every case
has to be reviewed by an experienced PEA surgeon for the assessment of operability. In this updated recom-
mendation, important contents of the European guidelines were commented, and more recent information
regarding diagnosis and treatment was added.
© 2011 Elsevier Ireland Ltd.
Preliminary remarks
This article is part of a supplement of the International Journal
of Cardiology in which the results of a Consensus Conference on
pulmonary hypertension are described that took place in June
2010 in Cologne, Germany, and was organized by the PH working
groups of the German Society of Cardiology (Deutsche Gesellschaft
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für Kardiologie, DGK), the German Society of Respiratory Medicine
(Deutsche Gesellschaft für Pneumologie, DGP) and the German
Society of Pediatric Cardiology (Deutsche Gesellschaft für pädi-
atrische Kardiologie, DGPK). This conference addressed practical
issues surrounding the implementation of the European Guidelines
for diagnosis and treatment of pulmonary hypertension in Ger-
many. To this end, a number of working groups was initiated, one
of which was speciﬁcally dedicated to the diagnosis and treatment
of chronic thromboembolic pulmonary hypertension (CTEPH). The
authors were members of this working group. The correspond-
ing articles were initially published in the Deutsche Medizinische
Wochenschrift, and the information was now updated in October
2011. Below, the corresponding sections of the European Guidelines
are summarized [1–3] whereby comments and additions appear in
italics. The information on class of recommendation and level of
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evidence correspond to the tables listed in the preamble of this
supplement.
1. Deﬁnition and pathogenesis
CTEPH is deﬁned as pre-capillary PH as assessed by right heart
catheterization (mean PAP ≥25 mmHg, PCWP ≤15 mmHg) in the
presence of multiple chronic/organized occlusive thrombi/emboli in
the elastic pulmonary arteries (main, lobar, segmental, subsegmen-
tal) after at least three months of effective anticoagulation [1,2].
CTEPH is thought to result from isolated or recurrent pulmonary
thromboembolism and represents one of the most prevalent forms
of PH. Although most patients with pulmonary embolism (PE) do
not develop CTEPH [4], the disease appears to be more preva-
lent than previously assumed [5]. Two prospective cohort studies
demonstrated a cumulative incidence of symptomatic CTEPH of
3.8% [6] and 1.5% [7] after acute PE, respectively. Nevertheless, it
is almost impossible to determine the overall prevalence of CTEPH
since not all of these patients have a history of acute PE. In fact,
CTEPH is frequently found in patients without any previous clinical
episode of acute PE or deep venous thrombosis (up to 50% in
different series) [8].
The pathogenesis of CTEPH is complex and has not been fully
understood [8]. The most important pathobiological process is non-
resolution of acute embolic masses which later undergo ﬁbrosis,
thus leading to mechanical obstruction of pulmonary arteries [1,2].
Unlike in acute PE, there is no linear correlation between a
compromised hemodynamic state and the mechanical obstruction
of pulmonary arteries. Pulmonary thromboembolism or in situ
thrombosis may be initiated or aggravated by abnormalities in
either the clotting cascade, endothelial cells, or platelets, all of
which interact in the coagulation process [5]. Thus, coagulation and
ﬁbrinolytic disorders are thought to contribute to the development
of the disease. In addition, other factors such as abnormal ﬁbrinogen
and immunological, inﬂammatory, or infectious mechanisms trigger
pathological remodeling of major and small pulmonary vessels as a
response to misguided thrombus resolution (Fig. 1).
Platelet abnormalities and biochemical features of a procoag-
ulant environment within the pulmonary vasculature support a
potential role for thrombus formation in initiating the disease in
some patients. In most cases, it remains unclear whether throm-
bosis and platelet dysfunction are a cause or consequence of the
disease. Inﬂammatory inﬁltrates are commonly detected in the
pulmonary endarterectomy (PEA) specimens [1,2].
While acute PE may be clinically silent [9], there is accumu-
lating evidence that CTEPH may also develop in the absence of
previous PE [8]. In these cases, the disease is probably initiated by
thrombotic or inﬂammatory lesions in the pulmonary vasculature.
Fig. 1. Current hypothesis for the pathobiology of CTEPH (according to [5,8].)
Once vessel obliteration is suﬃcient to cause increases in the PAP,
a process of pulmonary vascular remodeling is started which self-
perpetuates the progression of PH, even in the absence of further
thromboembolic events [1,2].
Pathological lesions are characterized by organized thrombi
tightly attached to the pulmonary arterial medial layer in the
elastic pulmonary arteries, replacing the normal intima. These may
completely occlude the lumen or form different grades of stenoses,
webs, and bands [4]. Interestingly, in the non-occluded areas, a pul-
monary arteriopathy indistinguishable from that of PAH (including
plexiform lesions) can develop [10]. Obstructive lesions observed
in the distal pulmonary arteries of non-obstructed areas may be
related to a variety of factors, such as shear stress, pressure, inﬂam-
mation, and the release of cytokines and vasculopathic mediators.
Collateral vessels from the systemic circulation (from bronchial,
costal, diaphragmatic and coronary arteries) can grow to reperfuse
at least partially the areas distal to complete obstructions [1,2].
2. Thrombophilia and CTEPH
Traditional risk factors for venous thromboembolism (VTE) in-
clude antithrombin deﬁciency, protein C deﬁciency, protein S deﬁ-
ciency, factor V Leiden, plasminogen deﬁciency, and anticardiolipin
antibodies [9]. However, in 147 consecutive patients with CTEPH,
the prevalence of hereditary thrombotic risk factors (antithrombin
mutations, protein S, protein C, factor II or factor V Leiden) was not
increased when compared to 99 consecutive patients with IPAH or
to 100 control patients (Table 1) [11].
Thrombophilia studies have shown that lupus anticoagulant may
be found in ∼10% of CTEPH patients, and 20% carry antiphospho-
lipid antibodies, lupus anticoagulant, or both [12]. A recent study
has demonstrated that the plasma level of factor VIII, a protein
associated with both primary and recurrent VTE, is elevated in 39%
of patients with CTEPH [12]. No abnormalities of ﬁbrinolysis have
been identiﬁed [1,2]. Blood groups type A, B, and AB were found to
be signiﬁcantly more common in patients with CTEPH compared to
patients with PAH (88% vs. 56%) [13].
Plasma lipoprotein levels (a) (Lp(a)), a subgroup of the low
density lipoprotein with high atherogenic potency, were signiﬁ-
cantly higher in patients with CTEPH than in patients with PAH
and control subjects, indicating an overlap of venous and arterial
thrombotic risk factors [14].
3. Factors that are associated with the development of CTEPH
In addition to thrombophilia, certain conditions are associ-
ated with an increased risk for CTEPH [1,2], including previous
splenectomy, the presence of a ventriculo-atrial (VA) shunt for the
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Table 1
Risk factors for CTEPH [6,11–15].
Independent clinical risk factors for CTEPH
• Splenectomy
• Ventriculo-atrial (VA) shunts
• Pacemaker leads
• Indwelling central venous catheters (e.g. Port, Hickman catheter)
• Chronic inﬂammatory diseases (osteomyelitis, inﬂammatory bowel
diseases)
• Malignant diseases
• Thyroid hormone replacement therapy
Risk factors associated with CTEPH after symptomatic PE
• Previous pulmonary embolism
• Young age
• Large perfusion defect
• Idiopathic PE at presentation
Plasmatic risk factors associated with CTEPH
• Elevated factor VIII levels >250%
• APA/LAC
• Combined coagulation defects
• Fibrinogen mutations
APA, antiphospholipid antibodies; LAC, lupus anticoagulans.
treatment of hydrocephalus, myeloproliferative disorders, infected
intravenous lines, and chronic inﬂammatory disorders, such as os-
teomyelitis and inﬂammatory bowel diseases [14–16]. While these
associated conditions have a negative impact on survival [17], the
mechanism(s) linking these conditions to CTEPH have not been
fully explored, but chronic inﬂammation or chronic blood stream
infection may play a critical role [13].
4. Diagnostic procedures
Any patient with unexplained PH should be evaluated for the
presence of CTEPH. Suspicion should be high when the patient
presents with a history of previous venous thromboembolism.
Survivors of acute PE should be followed after the acute episode
to detect signs and symptoms of CTEPH. Patients with acute PE
showing signs of PH or RV dysfunction at any time during their
hospital stay should receive a follow-up echocardiography after
discharge (usually after 3-6 months) to determine whether or not
PH has resolved [1,2].
In patients with unexplained PH, a ventilation/perfusion lung
scan (comment: planar images on at least 6 views + SPECT) is recom-
mended to exclude CTEPH [18,19], since the sensitivity is greater
than that of computed tomography [20]. While a normal venti-
lation/perfusion lung scan rules out CTEPH, unmatched perfusion
defects can also occur in other conditions (see Table 2).
Multidetector-row CT angiography is indicated when the ven-
tilation/perfusion lung scan is indeterminate or reveals perfusion
defects (see speciﬁc recommendations of the working group). Even
in the era of modern multirow CT scanners, there is not yet
enough evidence to suggest that a normal CT angiography excludes
the presence of operable CTEPH [1,2]. Nevertheless, CT angiog-
raphy may show complete obstruction, stenoses, strictures, or
intimal irregularities [21,22]. Parenchymal lesions and hypertrophic
bronchial collaterals are visualized.
Once perfusion/ventilation scanning and/or CT angiogram show
signs compatible with CTEPH, the patient should be referred to
a center with expertise in the medical and surgical management
of these patients [1,2]. To determine the appropriate therapeutic
strategy, invasive tools including right heart catheterization and
traditional pulmonary angiography are usually required [4]. Coro-
nary angiography is indicated in candidates for PEA and risk factors
for coronary heart disease. In order to minimize risks and repeated
procedures, these investigations should be performed at an expert
center rather than at the referring hospitals [23].
Table 2
Differential diagnosis of CTEPH (by localization of the lesion).
1. Pre-capillary
• acute pulmonary embolism
• PAH
• in situ thrombosis in congenital heart disease
• mediastinal ﬁbrosis
• vasculitis
• sarcoidosis
• pulmonary artery sarcoma
• non-thrombotic embolism
– tumor
– parasites
– histoplasmosis
– foreign bodies (talcum)
• Osler’s disease
• pulmonary atresia
• Swyer James syndrome
• Recklinghausen’s disease
• hemoglobinopathy
2. Capillary
• capillary hemangiomatosis
3. Post-capillary
• pulmonary veno-occlusive disease (PVOD)
• mediastinal ﬁbrosis
• schistosomiasis
Fig. 2. Diagnostic algorithm for CTEPH.
The ﬁnal diagnosis of CTEPH is based on the presence of pre-
capillary PH as assessed by right heart catheterization (mean PAP
≥25 mmHg, PCWP 15 mmHg, PVR >2 Wood units) in patients with
mutiple chronic/organized occlusive thrombi/emboli in the elastic
pulmonary arteries (main, lobar, segmental, subsegmental) [1,2].
Furthermore, the decision about potential PEA is made by review-
ing the patient history and functional class, ventilation/perfusion
lung scan, selective pulmonary angiography, CT angiography, and
right heart catheterization (Fig. 2, Table 3). Blood group and
thrombophilia screening including AT III, lupus anticoagulant, and
anti-cardiolipin antibodies should be performed.
Comments:
The diagnostic tools to assess the severity of CTEPH are the same as
for PAH. There is, however, less available data for patients with CTEPH
than for patients with PAH.
Table 3
Diagnostic criteria in CTEPH.
The ﬁnal diagnosis of CTEPH is based on the presence of:
1. Symptomatic PH
2. PAPm ≥25 mmHg, PAWP ≤15 mmHg, or non-measurable PAWP
3. With chronic/organized thrombi/emboli in the elastic pulmonary
arteries (main, lobar, segmental, or subsegmental level)
4. After at least three months of effective anticoagulation.
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Other imaging procedures such as MRI [24] and angioscopy [25] are
not mentioned in the ESC/ERS guidelines but may be applied depending
on the experience of the respective center.
In order to determine the therapeutic strategy for patients with
CTEPH, one study suggested that vasoreactivity testing may be used
within the scope of right heart catheterization [26], although the
consequences of such testing remain unclear. Analysis of the pressure
decay curves in right heart catheterization during pulmonary arterial
occlusion can help identify a distal component of vasculopathy [27].
Speciﬁc recommendations of the working group:
1. (a) Patients with persistent dyspnea after acute PE should be
followed up, and the presence of CTEPH should be included into
the spectrum of differential diagnoses.
(b) Stable patients with signs of signiﬁcant PH at the time of
the thromboembolic event should undergo assessment for the
presence of CTEPH three months after the event during which
the patient should have received effective anticoagulation.
(c) The diagnostic work-up should include echocardiography, perfu-
sion scanning, CT angiography, right heart catheterization, and,
if necessary, pulmonary angiography.
2. CT alone is not suﬃcient to refute the diagnosis or inoperability
of a patient with CTEPH. In fact, it is a common observation in
PEA centers that CTEPH patients are referred late, after previous
misdiagnoses that were based on “negative“ CT-scans. Pulmonary
angiography is the standard procedure for the evaluation of oper-
ability. Selective pulmonary angiography in at least two planes is
mandatory and allows visualization of the morphology of segmental
and subsegmental arteries, as well as visualization of parenchy-
mal perfusion. CT and MRI currently constitute valuable adjunctive
imaging modalities (see Fig. 2).
5. Treatment of CTEPH
Patients with CTEPH should receive life-long anticoagulation,
usually with vitamin K antagonists adjusted to a target INR between
2.0 and 3.0.
The decision on how to treat patients with CTEPH should be
made at an expert center based upon interdisciplinary discussion
among internists, radiologists, and expert surgeons. Pulmonary
endarterectomy (PEA) is the treatment of choice for patients with
CTEPH as it is a potentially curative treatment option. As a rule,
a patient should not be considered inoperable as long as the case
has not been reviewed by an experienced PEA surgeon. Detailed
pre-operative patient evaluation and selection, surgical technique
and experience, and meticulous post-operative management are
essential prerequisites for success after this intervention [21].
The selection of patients for surgery depends on the extent and
location of the organized thrombi in relation to the degree of
PH, and taking into consideration age and co-morbidities. Proximal
organized thrombi represent the ideal indication, while more distal
obstructions may complicate or prevent a successful procedure.
After an effective intervention, a dramatic drop of pulmonary
vascular resistance can be expected with a near normalization of
pulmonary hemodynamics. A center can be considered to have
suﬃcient expertise in this ﬁeld if it performs at least 20 PEA
operations per year with a mortality rate <10% [1,2].
Speciﬁc PAH drug therapy has thus far not proven effective in
CTEPH. However, targeted treatments may be considered in selected
patients with CTEPH, mainly for three different scenarios: (i) if pa-
tients are not considered candidates for surgery; (ii) if pre-operative
treatment is deemed appropriate to improve hemodynamics, and
(iii) if patients present with symptomatic residual/recurrent PH
after PEA or develop PH once more after PEA had been performed
[1,2]. Several uncontrolled clinical studies suggest that prostanoids,
endothelin receptor antagonists, and phosphodiesterase type-5 in-
Table 4
Recommendations of the ESC/ERS guidelines for CTEPH [1,2].
Recommendation Class of recom-
mendation
Level of
evidence
The diagnosis of CTEPH is based on the
presence of pre-capillary PH (mean PAP ≥25
mmHg, PCWP ≤15 mmHg, PVR >2 Wood
units) in patients with multiple
chronic/organized occlusive thrombi/emboli in
the elastic pulmonary arteries (main, lobar,
segmental, subsegmental), persisting after
effective anticoagulation over a minimum
period of three months.
I C
In patients with CTEPH, lifelong
anticoagulation is indicated.
I C
Surgical pulmonary endarterectomy (PEA) is
the recommended treatment for patients with
CTEPH.
I C
Once perfusion scanning and/or CT
angiography shows signs compatible with
CTEPH, the patient should be referred to a
center with expertise in surgical pulmonary
endarterectomy.
IIa C
The selection of patients for surgery should be
based on the extent and location of the
organized thrombi, on the degree of PH, and
on the presence of co-morbidities.
IIa C
PAH-speciﬁc drug therapy may be indicated in
selected CTEPH patients such as patients who
are not candidates for surgery or patients with
residual PH after pulmonary endarterectomy.
IIb C
hibitors may exert hemodynamic and clinical beneﬁts in patients
with CTEPH, regardless of whether these patients were considered
operable or inoperable [28–35]. The only randomized, placebo-
controlled clinical trial that has so far addressed the safety and
eﬃcacy of targeted medical treatment was the BENEFIT study
(Bosentan Effects in inoperable Forms of chronic thromboembolic pul-
monary hypertension), which investigated the effects of bosentan
in patients with inoperable CTEPH for a 16-week period [36]. This
study revealed a signiﬁcant drop in PVR in the bosentan group but
no change in the 6-minute walking test, WHO functional class, or
time to clinical worsening [1,2].
Given these limited data, further studies are necessary to obtain
reliable long-term data on the effect of medical therapies in patients
with CTEPH, and these patients should be treated within clinical
trials whenever possible. For the present time, no medical therapy
has been approved for CTEPH in Europe or the USA. Bilateral
lung transplantation is an option for advanced cases that are not
suited to PEA. The recommendations of the ESC/ERS guidelines for
CTEPH are summarized in Table 4 [1,2] and included in the speciﬁc
recommendations of the working group.
Comment:
A PEA center is deﬁned as an institution which performs ≥ 20
PEA surgeries per year with a mortality rate <10% [1,2]. Due to
the location of stenoses and occlusions of the pulmonary artery
branches at the segmental and subsegmental level as well as the
variable texture of obstructive material, the intervention is regarded
to be technically challenging. Complete disobliteration of the vessels
is necessary for maximal RV after-load reduction. Phases of deep
hypothermic circulatory arrest allow a better view of the pulmonary
arterial branches, and PEA has therefore to be carried out under a
considerably limited amount of time. In a recent randomized study,
circulatory arrest for PEA surgery has been shown to be a safe
procedure with regard to neurocognitive function [37].
Contraindications for PEA include severe left ventricular systolic
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dysfunction, advanced lung disease (e.g. COPD, pulmonary ﬁbrosis),
and malignant tumors with signiﬁcantly limited prognosis. Advanced
age per se is no contraindication for surgery.
To evaluate surgical accessibility, it is highly recommended to
obtain the expert opinion of a second PEA surgeon if in doubt.
The best surgical results are achieved with complete endarterectomy
and early postoperative reduction of PVR to <500 dyn s cm−5 (6.25
Wood units). The surgical technique (phases of circulatory arrest to
ensure a blood-free operating ﬁeld with adequate brain protection)
was ﬁrst described by the group in San Diego [38]. This group redeﬁned
the concept of non-operability by institutional rather than anatomical
limitations. For example, there is no deﬁnition for “distal obstructions”.
Instead, “distal” depends on the experience of the surgeon.
Even though the results of PEA in patients with CTEPH have
not been assessed in randomized studies, the long-term results with
regard to survival, WHO functional class, exercise capacity, quality of
life, right ventricular function, hemodynamics, and gas exchange are
reported to be excellent for most patients. Recently, the results two
prospective large series have been published [39,40]. First results of an
international CTEPH registry, that included 386 consecutive patients
with newly diagnosed CTEPH (from February 2007 to January 2009)
undergoing surgery at 26 centers in Europe and 1 center in Canada,
showed a highly signiﬁcant and sustained decrease in PVR from 736
to 248 dyn s cm−5 (95% conﬁdence limit, 702–827 and 230–263,
respectively) at the end of intensive care, that was accompanied
by substantial improvements of WHO functional class and exercise
capacity (increase in 6MWD from 362 to 459 m; 95% CL, 340–399
and 440–473, respectively) at 1 year [39]. In line with these results,
a decrease in the PVR from 805 ± 365 to 301 ± 232 dyn s cm−5,
and an increase of the 6MWD from 269 ± 119 to 367 ± 108 m was
reported in 314 patients who underwent PEA in a continuous national
series (1997–2007) in the UK [40]. The reported rates of residual PH
after PEA (mean PAP >30 mmHg) were 16.7% and 31%, respectively
[39,40].
Recent evidence implicates that PEA may also be successfully
performed in pediatric patients (reported age 8–18 years) [41]. In 17
reported cases, there were signiﬁcant improvements in the mean PAP
(45.5 ± 20.7 to 27.3 ± 13.0 mmHg), PVR (929 ± 844 to 299 ±
307 dyn s cm−5), and CO (3.8 ± 1.1 to 5.6 ±1.6 l/min), and long-
term survival (5+ years) was achieved in 87.5%. However, the rate of
rethrombosis appeared to be signiﬁcantly higher in children (38%) as
compared to adults (1–4%) [41].
The concept of PEA which was originally developed in San Diego
was adopted by approximately 20 larger centers worldwide. In 2008,
a perioperative mortality rate of 4.7% after PEA in 1,100 surgeries was
reported in an international prospective registry [38]. More recently,
they even reported a surgical mortality rate of 2.2%. Similarly, early
mortality after PEA was reported to be era-dependent in the UK series
(25% for 1997–2002; 2.7% for 2006–2007) [40]. With increasing expe-
rience, PEA centers worldwide should achieve perioperative mortality
rates <10%. This goal may be achieved by education and training at
the experienced centers, since the results are subject to a learning
curve. The impact of experience and surgical case volume on the
mortality rate have been conﬁrmed by the data of the international
CTEPH registry: In-hospital mortality at centers with less than 10 PEA
operations per year was 7.4% whereas the mortality rate at expert
centers with more than 50 operations per year was 3.5% [39].
In order to detect persistent or recurrent PH, systematic follow-up
investigations are necessary. Right heart catheterization is recom-
mended 6–12 months after PEA.
The inherent danger of initiating medical therapy without consult-
ing a PEA surgeon is that potentially operable patients are not referred
to a PEA center at all or only after delays, and they are therefore denied
a potentially curative therapy or are presented for surgery only at a
very advanced stage which is associated with a signiﬁcantly increased
risk for surgery. The availability of medical therapy should not imply
that operable patients are no longer referred for PEA. Corresponding
treatment decisions should therefore only be made at experienced
centers (see speciﬁc recommendations of the working group).
Speciﬁc recommendations of the working group
1. Operable patients:
These patients should undergo surgery (PEA) without delay. For
high-risk patients, the decision about the time of surgery and a
potential medical therapy prior to surgery should be made together
with a PEA surgeon.
2. Operable patients not undergoing surgery for various reasons
(comorbidities, patient refusal):
The decision not to operate on such patients may only be taken at
expert centers together with the responsible PEA surgeon. If surgery
is not an option, medical therapy with targeted PAH drugs may be
considered.
3. Technically non-operable patients:
The decision against surgery may only be taken at expert centers
together with the responsible PEA surgeon. If surgery is not an
option, medical therapy with targeted PAH drugs may be considered.
4. Persistent and recurrent PH after PEA:
The indication for repeated surgery should be reviewed at a PEA
center. If re-PEA is not indicated, medical therapy with targeted PAH
drugs may be considered.
Medical therapy of CTEPH:
There are no randomized, controlled studies that demonstrate clin-
ical eﬃcacy of targeted PAH drugs in patients with CTEPH [42,43].
Accordingly, no drug has so far been approved for this disease in Eu-
rope. However, "PAH drugs" should not be denied to selected patients
who may beneﬁt from them. This applies especially to patients with
inoperable CTEPH who, in some cases, cannot be clearly distinguished
from PAH. The working group believes that the following recommenda-
tions regarding medical treatment of these patients are acceptable:
• Targeted treatment with PAH drugs should only be initiated at ex-
perienced centers (deﬁnition according to the European guidelines,
see Table 4).
• The use of medical treatment requires comprehensive diagnostic
procedures according to the recommendations of the guidelines,
including the referral to a PEA surgeon, to ensure that the patients
are non-operable and that other causes of PH are excluded.
• Before these patients are treated with a targeted PAH therapy, it
should be assessed if they are eligible for a clinical study. Large PH
centers as well as PH self-support groups (in Germany: phev) can
provide further information about on-going clinical trials.
• Unlike in PAH, it is not yet known if PAH drugs have a positive
effect on disease progression in patients with CTEPH. It should
therefore be considered to attempt initial treatment over a limited
period of time such as 6 months, and to subsequently decide after
careful re-evaluation if an objective clinical improvement justifying
continuation of therapy was achieved. Otherwise the treatment
may be discontinued. This procedure and potential therapeutic
goals should be determined and documented together with the
patient prior to initiation of treatment.
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